Who Paid My Doc
Virginia Kraus
Rheumatology Durham, NC Medical Doctor
NPI 1013091172 CMS profile 363540
2100 Erwin Rd, Durham, NC 27710
General payments
$30,840
Research payments
$468,820
Ownership & investment interest
$0
Research they led as principal investigator
$150,000
Through program year 2025, Virginia Kraus of Durham, NC is reported in the CMS Open Payments database as having received $30,840 across 20 general payments and $468,820 in research payments paid to them. Separately, studies naming them as principal investigator received $150,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19,379 | 12 | |
| 2023 | General | $1,526 | 2 | |
| 2023 | Research | $25,000 | 1 | |
| 2022 | General | $3,220 | 1 | |
| 2022 | Research | $93,820 | 1 | |
| 2021 | Research | $160,000 | 2 | |
| 2020 | General | $3,570 | 3 | |
| 2020 | Research | $160,000 | 1 | |
| 2019 | General | $3,146 | 2 | |
| 2019 | Research | $30,000 | 2 |
Beside peers
- Virginia Kraus
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Virginia Kraus were reported at $19,379. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Virginia Kraus | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,146 | $744 | $153–$2,687 | $163 |
| 2020 | $3,570 | $462 | $98–$2,027 | $114 |
| 2021 | $0 | $531 | $101–$2,153 | $132 |
| 2022 | $3,220 | $627 | $125–$2,303 | $149 |
| 2023 | $1,526 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $19,379 | $903 | $171–$2,775 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$2,809
Medicare patients
14
Services billed
28
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
27 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Rheumatology in North Carolina
Related records
Rheumatology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.